Prostatic-specific antigen (PSA) levels in patients with polycystic ovary syndrome (PCOS): a meta-analysis

Table 1 Description of included studies

Source	Year	Country	Sample Size (PCOS/CG)	Study design	Mean BMI (kg/m²)		Mean Age, y
Source	Year	Country	Sample Size (PCOS/CG)	Study design	PCOS	CG	PCOS	CG
Bahceci et al. [19]^a	2004	Turkey	30/30	Case-control	22.8 ± 5	21 ± 2.4	22.4 ± 3.9	22.7 ± 1.4
Bili et al. [20]	2014	Greece	43/40	Case-control	24.9 ± 5.9	22.7 ± 3.7	28.9 ± 5.0	30.8 ± 4.3
Gullu et al. [12]^a	2003	Turkey	33/20	Case-control	26.04 ± 7.70	24.13 ± 6.67	23.04 ± 4.64	27.92 ± 7.81
Mardanian et al. [21]	2011	Iran	32/32	Case-control	24.78 ± 2.96	23.19 ± 2.24	26.38 ± 4.8	27.1 ± 4.9
Tokmak et al. [22]	2018	Turkey	42/47	Case-control	23.8 ± 4.6	20.8 ± 2.9	19 ± 2	18 ± 3
Ukinc A et al. [23]^a,b	2009	Turkey	42/35	Case-control	26.35 ± 7.05	26.1 ± 6.9	23.29 ± 5.95	25.4 ± 5.0
Ukinc B et al. [23]^a,b	2009	Turkey	20/35	Case-control	25.55 ± 5.29	26.1 ± 6.9	25.45 ± 9.36	25.4 ± 5.0
Vural et al. [7]	2007	Turkey	43/43	Case-control	23.45 ± 4.70	21.52 ± 3.01	21.4 ± 1.88	20.8 ± 2.28

Free androgen index (FAI) = total testosterone (TT)*100/sex hormone binding globulin (SHBG)
Data are expressed as mean ± SD
Abbreviations: PCOS Polycystic ovary syndrome, CG Control group, NG Not given, BMI Body mass index, PSA Prostatic specific antigen, LH Luteinizing hormone, FSH Follicle stimulating hormone
^aData included total PSA and free PSA
^bData included two subgroups PCOS patients: anovulatory PCOS (Group A) and ovulatory PCOS (Group B)

ISSN: 1757-2215